🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jefferies Group’s ANIP Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q4 2025
+12,000 Shares
Current Position
12,000 Shares
$922,800 Value

Jefferies Group's ANIP Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 12,000 shares of ANI Pharmaceuticals, Inc. (ANIP) worth $922,800, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Jefferies Group has initiated a new position in ANIP, representing a fresh investment thesis on this company.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's ANI Pharmaceuticals (ANIP) Holding Value Over Time

Track share changes against reported price movement

Quarterly ANI Pharmaceuticals (ANIP) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +12,000 New Buy 12,000 $78.94

Jefferies Group's ANI Pharmaceuticals Investment FAQs

Jefferies Group first purchased ANI Pharmaceuticals, Inc. (ANIP) in Q4 2025, acquiring 12,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held ANI Pharmaceuticals, Inc. (ANIP) for 2 quarters since Q4 2025.

Jefferies Group's largest addition to ANI Pharmaceuticals, Inc. (ANIP) was in Q4 2025, adding 12,000 shares worth $947,280.

According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 12,000 shares of ANI Pharmaceuticals, Inc. (ANIP), valued at approximately $922,800.

As of the Q1 2026 filing, ANI Pharmaceuticals, Inc. (ANIP) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in ANI Pharmaceuticals, Inc. (ANIP) was 12,000 shares, as reported at the end of Q4 2025.